| Year |
Citation |
Score |
| 2019 |
Kuo MT, Long Y, Tsai WB, Li YY, Chen HHW, Feun LG, Savaraj N. Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors. Translational Oncology. 13: 355-364. PMID 31887630 DOI: 10.1016/J.Tranon.2019.12.003 |
0.366 |
|
| 2019 |
Nguyen DJ, Theodoropoulos G, Li YY, Wu C, Sha W, Feun LG, Lampidis TJ, Savaraj N, Wangpaichitr M. Targeting the kynurenine pathway for the treatment of cisplatin resistant lung cancer. Molecular Cancer Research : McR. PMID 31628200 DOI: 10.1158/1541-7786.Mcr-19-0239 |
0.424 |
|
| 2019 |
Savaraj N, Li Y, Wu C, Wangpaichitr M, Spector S, Sentome M, Feun LG. Abstract 4747: Surviving skills in melanoma cells: An important consideration to both targeted and immunological approach in the treatment of melanoma Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4747 |
0.307 |
|
| 2019 |
Wangpaichitr M, Nguyen DJ, Li Y, Wu C, Feun LG, Savaraj N. Abstract 4361: Kynurenine - Aryl hydrocarbon receptor axis: A crucial modulator of immunometabolism in cisplatin resistant lung cancer Cancer Research. 79: 4361-4361. DOI: 10.1158/1538-7445.Sabcs18-4361 |
0.399 |
|
| 2018 |
Roeksomtawin S, Navasumrit P, Waraprasit S, Parnlob V, Sricharunrat T, Bhudhisawasdi V, Savaraj N, Ruchirawat M. Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines. Oncology Letters. 16: 1529-1538. PMID 30008833 DOI: 10.3892/Ol.2018.8807 |
0.402 |
|
| 2018 |
Wangpaichitr M, Wu C, Nguyen DJ, Li Y, Feun LG, Savaraj N. Abstract 5478: Targeting kynurenine pathway for the treatment of cisplatin-resistant lung cancer Cancer Research. 78: 5478-5478. DOI: 10.1158/1538-7445.Am2018-5478 |
0.365 |
|
| 2018 |
Wu C, Li Y, Wangpaichitr M, Feun LG, Kuo MT, Savaraj N. Abstract 3642: Relationship of argininosuccinate synthetase (ASS) and PD-L1 expression in arginine enriched or depleted environment in melanoma Cancer Research. 78: 3642-3642. DOI: 10.1158/1538-7445.Am2018-3642 |
0.332 |
|
| 2017 |
Li YY, Wu C, Shah SS, Chen SM, Wangpaichitr M, Kuo MT, Feun LG, Han X, Suarez M, Prince J, Savaraj N. Degradation of AMPK-α1 Sensitizes BRAF Inhibitor-Resistant Melanoma Cells to Arginine Deprivation. Molecular Oncology. PMID 29094484 DOI: 10.1002/1878-0261.12151 |
0.395 |
|
| 2017 |
Li YY, Feun LG, Thongkum A, Tu CH, Chen SM, Wangpaichitr M, Wu C, Kuo MT, Savaraj N. Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy. International Journal of Molecular Sciences. 18. PMID 28629173 DOI: 10.3390/Ijms18061297 |
0.338 |
|
| 2017 |
Thongkum A, Wu C, Li YY, Wangpaichitr M, Navasumrit P, Parnlob V, Sricharunrat T, Bhudhisawasdi V, Ruchirawat M, Savaraj N. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma. International Journal of Molecular Sciences. 18. PMID 28587170 DOI: 10.3390/Ijms18061175 |
0.376 |
|
| 2017 |
Wangpaichitr M, Wu C, Li YY, Nguyen DJM, Kandemir H, Shah S, Chen S, Feun LG, Prince JS, Kuo MT, Savaraj N. Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer. Oncotarget. PMID 28525376 DOI: 10.18632/Oncotarget.17568 |
0.392 |
|
| 2017 |
Savaraj N, Chen S, Wu C, Li Y, Wangpaichitr M, Benveniste R, Feun LG. The role of procollagen alpha 1 type 1 (Col1A1) on invasion and cellular signaling in glioma cells. Journal of Clinical Oncology. 35: e23165-e23165. DOI: 10.1200/Jco.2017.35.15_Suppl.E23165 |
0.344 |
|
| 2017 |
Wangpaichitr M, Wu C, Li YY, Feun LG, Kuo MT, Savaraj N. Abstract 4404: Novel approach to circumvent cisplatin resistant lung cancer by targeting metabolism Cancer Research. 77: 4404-4404. DOI: 10.1158/1538-7445.Am2017-4404 |
0.301 |
|
| 2016 |
Long Y, Tsai WB, Wang D, Hawke DH, Savaraj N, Feun LG, Hung MC, Chen HH, Kuo MT. Argininosuccinate Synthetase 1 (ASS1) Is a Common Metabolic Marker of Chemosensitivity for Targeted Arginine- and Glutamine-Starvation Therapy. Cancer Letters. PMID 27913198 DOI: 10.1016/J.Canlet.2016.11.028 |
0.344 |
|
| 2016 |
Bhatia S, Pereira K, Mohan P, Narayanan G, Wangpaichitr M, Savaraj N. Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to know. The Indian Journal of Radiology & Imaging. 26: 81-91. PMID 27081229 DOI: 10.4103/0971-3026.178347 |
0.324 |
|
| 2016 |
Li YY, Wu C, Chen SM, Shah SS, Wangpaichitr M, Feun LG, Kuo MT, Suarez M, Prince J, Savaraj N. BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma. Oncotarget. PMID 26771234 DOI: 10.18632/Oncotarget.6882 |
0.414 |
|
| 2016 |
Chen S, Wu C, Li Y, Wangpaichitr M, Benveniste RJ, Turkson J, Savaraj N, Feun LG. Abstract 3712: The relationship of Procollagen alpha 1 type 1 (Col1A1) / DDR2 signaling in malignant glioma and sensitivity to STAT 3/5 inhibitor Cancer Research. 76: 3712-3712. DOI: 10.1158/1538-7445.Am2016-3712 |
0.407 |
|
| 2016 |
Li Y, Wu C, Shah S, Chen S, Wangpaichitr M, Feun L, Kuo M, Suarez M, Savaraj N. Abstract 2671: BRAF inhibitor resistance reprograms metabolic and survival pathways to sensitize melanoma cells to arginine deprivation Cancer Research. 76: 2671-2671. DOI: 10.1158/1538-7445.Am2016-2671 |
0.423 |
|
| 2016 |
Wangpaichitr M, Wu C, Li YY, Shah S, Chen S, Dinh V, Kuo MT, Feun LG, Savaraj N. Abstract 1038: Exploiting ROS and metabolic differences to selectively killing cisplatin resistant lung cancer Cancer Research. 76: 1038-1038. DOI: 10.1158/1538-7445.Am2016-1038 |
0.373 |
|
| 2015 |
Tsai WB, Long Y, Park JR, Chang JT, Liu H, Rodriguez-Canales J, Savaraj N, Feun LG, Davies MA, Wistuba II, Kuo MT. Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents. Oncogene. PMID 26096933 DOI: 10.1038/Onc.2015.237 |
0.346 |
|
| 2015 |
Chen HH, Chen WC, Liang ZD, Tsai WB, Long Y, Aiba I, Fu S, Broaddus R, Liu J, Feun LG, Savaraj N, Kuo MT. Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. Expert Opinion On Therapeutic Targets. 1-11. PMID 26004625 DOI: 10.1517/14728222.2015.1043269 |
0.346 |
|
| 2015 |
Savaraj N, Wu C, Li YY, Wangpaichitr M, You M, Bomalaski J, He W, Kuo MT, Feun LG. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin. Oncotarget. 6: 6295-309. PMID 25749046 DOI: 10.18632/Oncotarget.3370 |
0.402 |
|
| 2015 |
Chen S, Wu C, Li YY, Wangpaichitr M, Feun LG, Benveniste R, Dinh V, Savaraj N. Abstract 43: The role of discoidin domain receptor 2 (DDR2) and its relationship with procollagen alpha 1 type 1(Col1A1) in malignant glioma Cancer Research. 75: 43-43. DOI: 10.1158/1538-7445.Am2015-43 |
0.39 |
|
| 2015 |
Li Y, Savaraj N, Wu C, Chen S, Wangpaichitr M, Kuo MT, Feun LG. Abstract 2900: Biochemical alterations in BRAF inhibitor (BRAFi) resistant melanoma cells increase their vulnerability to arginine deprivation Cancer Research. 75: 2900-2900. DOI: 10.1158/1538-7445.Am2015-2900 |
0.43 |
|
| 2015 |
Wangpaichitr M, Wu C, Nguyen DM, You M, Li YY, Chen S, Feun LG, Savaraj N. Abstract 1206: Cisplatin resistant non small cell lung cancer is sensitive to arginine deprivation therapy Cancer Research. 75: 1206-1206. DOI: 10.1158/1538-7445.Am2015-1206 |
0.427 |
|
| 2014 |
Liang ZD, Long Y, Chen HH, Savaraj N, Kuo MT. Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals. Journal of Biological Inorganic Chemistry : Jbic : a Publication of the Society of Biological Inorganic Chemistry. 19: 17-27. PMID 24132751 DOI: 10.1007/S00775-013-1051-Z |
0.341 |
|
| 2014 |
You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro. The Journal of Thoracic and Cardiovascular Surgery. 147: 508-16. PMID 24094913 DOI: 10.1016/J.Jtcvs.2013.08.035 |
0.349 |
|
| 2014 |
Matsangou M, Santos ES, Raez LE, Gomez JE, Dinh V, Savaraj N. Early-stage non-small-cell lung cancer: overview of adjuvant chemotherapy and promising advances Lung Cancer Management. 3: 85-99. DOI: 10.2217/Lmt.13.64 |
0.368 |
|
| 2014 |
Chen S, Wu C, You M, Tran M, Wangpaichitr M, Li YY, Benveniste RJ, Kuo MT, Savaraj N, Feun LG. Abstract 4192: Exploiting discoidin domain receptor (DDR) and collagen signaling as a new approach to treat human malignant gliomas Cancer Research. 74: 4192-4192. DOI: 10.1158/1538-7445.Am2014-4192 |
0.363 |
|
| 2014 |
Li Y, Wu C, Chen S, Wangpaichitr M, You M, Spector S, Feun LG, Kuo MT, Savaraj N. Abstract 3701: BRAF inhibitor (vemurafenib) resistance confers sensitivity to arginine deprivation in melanoma Cancer Research. 74: 3701-3701. DOI: 10.1158/1538-7445.Am2014-3701 |
0.451 |
|
| 2014 |
You M, Wangpaichitr M, Nguyen JD, Chapman JR, Cioffi-Lavina M, Savaraj N, Nguyen DM. Abstract 1435: Exploiting obligate arginine auxotrophy in tumor cells lacking arginino-succinate synthetase (ASS) expression to develop targeted molecular therapy for non-small cell lung cancer (NSCLC) Cancer Research. 74: 1435-1435. DOI: 10.1158/1538-7445.Am2014-1435 |
0.439 |
|
| 2014 |
Wangpaichitr M, Wu C, Li YY, Chen S, You M, Dinh V, Feun LG, Kuo MT, Savaraj N. Abstract 1428: Targeting metabolic alteration in cisplatin-resistant lung cancer Cancer Research. 74: 1428-1428. DOI: 10.1158/1538-7445.Am2014-1428 |
0.381 |
|
| 2014 |
Chen S, Wu C, Li Y, Feun L, Wangpaichitr M, Benveniste RJ, Savaraj N. CS-03 * UTILIZING COLLAGEN AND DISCOIDIN DOMAIN RECEPTOR SIGNALING AS A NEWTHERAPEUTIC STRATEGY IN HUMAN MALIGNANT GLIOMA Neuro-Oncology. 16: v51-v51. DOI: 10.1093/Neuonc/Nou242.3 |
0.346 |
|
| 2013 |
Long Y, Tsai WB, Wangpaichitr M, Tsukamoto T, Savaraj N, Feun LG, Kuo MT. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Molecular Cancer Therapeutics. 12: 2581-90. PMID 23979920 DOI: 10.1158/1535-7163.Mct-13-0302 |
0.4 |
|
| 2013 |
You M, Savaraj N, Kuo MT, Wangpaichitr M, Varona-Santos J, Wu C, Nguyen DM, Feun L. TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. Molecular and Cellular Biochemistry. 374: 181-90. PMID 23180246 DOI: 10.1007/S11010-012-1518-1 |
0.341 |
|
| 2013 |
Wangpaichitr M, Theodoropoulos G, Wu C, Poochareon N, Li YY, You M, Kuo MT, Feun LG, Savaraj N. Abstract 961: Selectively kill cisplatin resistant lung cancer cells by exploiting ROS and metabolic differences. Cancer Research. 73: 961-961. DOI: 10.1158/1538-7445.Am2013-961 |
0.412 |
|
| 2013 |
Feun LG, Narayanan G, Yrizarry J, Dinh V, Savaraj N, O'Brien C, Martin P. Abstract 4674: Pilot study of intrahepatic artery chemotherapy in combination with sorafenib in hepatocellular carcinoma patients. Cancer Research. 73: 4674-4674. DOI: 10.1158/1538-7445.Am2013-4674 |
0.331 |
|
| 2013 |
You M, Chen S, Wu C, Li Y, Feun L, Wangpaithitr M, Dinh V, Savaraj N. Abstract 4052: Targeting procollagen secretory pathway for the treatment of primary brain tumor through ER stress. Cancer Research. 73: 4052-4052. DOI: 10.1158/1538-7445.Am2013-4052 |
0.374 |
|
| 2013 |
You M, Santos JV, Robbins DJ, Savaraj N, Nguyen DM. Abstract 3246: Pharmacologic targeting of the Hedgehog (HH) signal transduction pathway significantly suppresses growth of malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) cells in vitro. Cancer Research. 73: 3246-3246. DOI: 10.1158/1538-7445.Am2013-3246 |
0.396 |
|
| 2012 |
Kuo MT, Fu S, Savaraj N, Chen HH. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Research. 72: 4616-21. PMID 22962276 DOI: 10.1158/0008-5472.Can-12-0888 |
0.326 |
|
| 2012 |
Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Molecular Cancer Therapeutics. 11: 2483-94. PMID 22914438 DOI: 10.1158/1535-7163.Mct-12-0580 |
0.4 |
|
| 2012 |
Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, Sisson W, Jungbluth AA, Bomalaski J, Savaraj N. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. British Journal of Cancer. 106: 1481-5. PMID 22472884 DOI: 10.1038/Bjc.2012.106 |
0.327 |
|
| 2012 |
Tsai WB, Aiba I, Long Y, Lin HK, Feun L, Savaraj N, Kuo MT. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Research. 72: 2622-33. PMID 22461507 DOI: 10.1158/0008-5472.Can-11-3605 |
0.336 |
|
| 2012 |
Wangpaichitr M, Sullivan EJ, Theodoropoulos G, Wu C, You M, Feun LG, Lampidis TJ, Kuo MT, Savaraj N. The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Molecular Cancer Therapeutics. 11: 604-15. PMID 22248473 DOI: 10.1158/1535-7163.Mct-11-0599 |
0.396 |
|
| 2012 |
Savaraj N, Xu R, Landy H, Lai S, Sternau L, Solomon J, Wu C, Lampidis T, Feun L. Comparison of topoisomerase I and II expression in primary brain tumor and lung cancer. Oncology Reports. 4: 857-61. PMID 21590157 DOI: 10.3892/Or.4.4.857 |
0.325 |
|
| 2012 |
Wangpaichitr M, Theodoropoulos G, Wu C, You M, Feun LG, Kuo MT, Lampidis TJ, Savaraj N. Abstract 1138: The emerging role of thioredoxin-1 on ROS and metabolic reprogramming in cisplatin resistant lung cancer Cancer Research. 72: 1138-1138. DOI: 10.1158/1538-7445.Am2012-1138 |
0.4 |
|
| 2011 |
Santos JV, You M, Wangpaichitr M, Savaraj N, Nguyen DM. Abstract LB-222: Identifying cFLIP as a marker and also a potentially “druggable” target of SAHA+TRAIL (TNF-Related Apoptosis Inducing Ligand), cytotoxicity in malignant pleural mesothelioma (MPM) Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-222 |
0.406 |
|
| 2011 |
You M, Savaraj N, Wangpaichitr M, Wu C, Kuo MT, Feun L. Abstract 4096: TRAIL enhances cytotoxicity of arginine depletion therapy in argininosuccinate synthetase-negative melanoma cells through interruption of autophagy via activation of caspases Cancer Research. 71: 4096-4096. DOI: 10.1158/1538-7445.Am2011-4096 |
0.353 |
|
| 2011 |
Wangpaichitr M, Wu C, You M, Feun LG, Kuo MT, Dinh V, Savaraj N. Abstract 1692: Downregulation of thioredoxin-1 confers resistance to cisplatin and sensitivity to the ROS generating agent elesclomol Cancer Research. 71: 1692-1692. DOI: 10.1158/1538-7445.Am2011-1692 |
0.375 |
|
| 2010 |
Sasine JP, Savaraj N, Feun LG. Topoisomerase I inhibitors in the treatment of primary CNS malignancies: an update on recent trends. Anti-Cancer Agents in Medicinal Chemistry. 10: 683-96. PMID 21235438 DOI: 10.2174/187152010794479825 |
0.391 |
|
| 2010 |
Kuo MT, Savaraj N, Feun LG. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget. 1: 246-51. PMID 21152246 DOI: 10.18632/Oncotarget.135 |
0.41 |
|
| 2010 |
Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT, Feun LG. Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Current Molecular Medicine. 10: 405-12. PMID 20459375 DOI: 10.2174/156652410791316995 |
0.371 |
|
| 2010 |
You M, Savaraj N, Wangpaichitr M, Wu C, Kuo MT, Varona-Santos J, Nguyen DM, Feun L. The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochemical and Biophysical Research Communications. 394: 760-6. PMID 20227389 DOI: 10.1016/J.Bbrc.2010.03.066 |
0.404 |
|
| 2010 |
You M, Savaraj N, Wu C, Wangpaichitr M, Kuo MT, Dinh V, Feun LG. Abstract 61: Enhancing arginine deprivation therapy in melanoma by combining with cisplatin Cancer Research. 70: 61-61. DOI: 10.1158/1538-7445.Am10-61 |
0.413 |
|
| 2010 |
Xi H, Kurtoglu M, Liu H, Wangpaichitr M, You M, Savaraj N, Lampidis TJ. Abstract 4840: 2-Deoxy-D-glucose induces autophagy through endoplasmic reticulum stress rather than by lowering ATP Cancer Research. 70: 4840-4840. DOI: 10.1158/1538-7445.Am10-4840 |
0.349 |
|
| 2010 |
Wangpaichitr M, Wu C, Kuo Mt, You M, Dinh V, Feun L, Savaraj N. Abstract 4525: Targeting ROS to kill cisplatin-resistant cells Cancer Research. 70: 4525-4525. DOI: 10.1158/1538-7445.Am10-4525 |
0.394 |
|
| 2010 |
Santos JV, Vara A, Thomas C, Wangpaichitr M, You M, Savaraj N, Nguyen DM. Abstract 3489: Profound cytotoxicity of the histone deacetylase inhibitor SAHA (Suberoylanilide Hydroxamic Acid) and TRAIL (Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand) combination in malignant pleural mesothelioma Cancer Research. 70: 3489-3489. DOI: 10.1158/1538-7445.Am10-3489 |
0.372 |
|
| 2009 |
Wangpaichitr M, Wu C, You M, Maher JC, Dinh V, Feun LG, Savaraj N. N',N'-Dimethyl-N',N'-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS). Cancers. 1: 23-38. PMID 20535236 DOI: 10.3390/Cancers1010023 |
0.38 |
|
| 2009 |
Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Molecular Cancer Therapeutics. 8: 3223-33. PMID 19934275 DOI: 10.1158/1535-7163.Mct-09-0794 |
0.334 |
|
| 2008 |
Wangpaichitr M, Wu C, You M, Kuo MT, Feun L, Lampidis T, Savaraj N. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. European Journal of Pharmacology. 591: 124-7. PMID 18585380 DOI: 10.1016/J.Ejphar.2008.06.028 |
0.393 |
|
| 2008 |
Wangpaichitr M, Savaraj N, Maher J, Kurtoglu M, Lampidis TJ. Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Molecular Cancer Therapeutics. 7: 1506-13. PMID 18566221 DOI: 10.1158/1535-7163.Mct-07-2334 |
0.389 |
|
| 2008 |
Chen HH, Song IS, Hossain A, Choi MK, Yamane Y, Liang ZD, Lu J, Wu LY, Siddik ZH, Klomp LW, Savaraj N, Kuo MT. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Molecular Pharmacology. 74: 697-704. PMID 18523133 DOI: 10.1124/Mol.108.047969 |
0.359 |
|
| 2008 |
Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N. Arginine deprivation as a targeted therapy for cancer. Current Pharmaceutical Design. 14: 1049-57. PMID 18473854 DOI: 10.2174/138161208784246199 |
0.431 |
|
| 2008 |
Feun L, Savaraj N. Topoisomerase I inhibitors for the treatment of brain tumors. Expert Review of Anticancer Therapy. 8: 707-16. PMID 18471044 DOI: 10.1586/14737140.8.5.707 |
0.365 |
|
| 2007 |
Savaraj N, Wu C, Kuo MT, You M, Wangpaichitr M, Robles C, Spector S, Feun L. The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights. 2: 119-28. PMID 21901069 DOI: 10.4137/Dti.S0 |
0.39 |
|
| 2007 |
Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, Wangpaichitr M, Savaraj N, Lane AN, Lampidis TJ. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Molecular Cancer Therapeutics. 6: 3049-58. PMID 18025288 DOI: 10.1158/1535-7163.Mct-07-0310 |
0.385 |
|
| 2007 |
Dinh V, Feun L, Elgart G, Savaraj N. Merkel cell carcinomas. Hematology/Oncology Clinics of North America. 21: 527-44; ix. PMID 17548038 DOI: 10.1016/J.Hoc.2007.04.008 |
0.382 |
|
| 2007 |
Maher JC, Wangpaichitr M, Savaraj N, Kurtoglu M, Lampidis TJ. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Molecular Cancer Therapeutics. 6: 732-41. PMID 17308069 DOI: 10.1158/1535-7163.Mct-06-0407 |
0.372 |
|
| 2007 |
Feun LG, Marini A, Landy H, Markoe A, Heros D, Robles C, Herrera C, Savaraj N. Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors. Journal of Neuro-Oncology. 82: 177-81. PMID 17051317 DOI: 10.1007/S11060-006-9261-7 |
0.363 |
|
| 2006 |
Feun L, Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opinion On Investigational Drugs. 15: 815-22. PMID 16787144 DOI: 10.1517/13543784.15.7.815 |
0.341 |
|
| 2006 |
Tien Kuo M, Savaraj N. Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. Molecular Carcinogenesis. 45: 701-9. PMID 16652372 DOI: 10.1002/Mc.20240 |
0.318 |
|
| 2006 |
Kuo MT, Wei Y, Yang X, Tatebe S, Liu J, Troncoso P, Sahin A, Ro JY, Hamilton SR, Savaraj N. Association of fragile site-associated (FSA) gene expression with epithelial differentiation and tumor development. Biochemical and Biophysical Research Communications. 340: 887-93. PMID 16386706 DOI: 10.1016/J.Bbrc.2005.12.088 |
0.31 |
|
| 2005 |
Savaraj N, Wu C, Landy H, Wangpaijit M, Wei Y, Kuo MT, Robles C, Furst AJ, Lampidis T, Feun L. Procollagen alpha 1 type 1: a potential aide in histopathological grading of glioma. Cancer Investigation. 23: 577-81. PMID 16305983 DOI: 10.1080/07357900500276915 |
0.315 |
|
| 2005 |
Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Molecular Cancer. 4: 25. PMID 16033649 DOI: 10.1186/1476-4598-4-25 |
0.363 |
|
| 2005 |
Feun L, Marini A, Moffat F, Savaraj N, Hurley J, Mazumder A. Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma. Cancer Investigation. 23: 3-8. PMID 15779861 DOI: 10.1081/Cnv-46368 |
0.341 |
|
| 2005 |
Maher JC, Savaraj N, Priebe W, Liu H, Lampidis TJ. Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas. 30: e34-9. PMID 15714127 DOI: 10.1097/01.Mpa.0000153327.46945.26 |
0.309 |
|
| 2005 |
Feun LG, Marini A, Landy H, Markoe A, Heros D, Savaraj N. Clinical and pharmacological study of CPT-11 and VM-26/VP-16 for patients with recurrent malignant primary brain tumors Journal of Clinical Oncology. 23: 1558-1558. DOI: 10.1200/Jco.2005.23.16_Suppl.1558 |
0.393 |
|
| 2004 |
Landy H, Markoe A, Potter P, Lasalle G, Marini A, Savaraj N, Reis I, Heros D, Wangpaichitr M, Feun L. Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma. Journal of Neuro-Oncology. 67: 215-20. PMID 15072470 DOI: 10.1023/B:Neon.0000021825.41221.B5 |
0.361 |
|
| 2004 |
Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Research. 64: 31-4. PMID 14729604 DOI: 10.1158/0008-5472.Can-03-3294 |
0.399 |
|
| 2004 |
Feun LG, Marini A, Echenique A, Guerra JJ, Yrizarry JM, Stadtlander K, Savaraj N, Jeffers L, Obrien C, Schiff E. Phase II study of lipiodol chemoembolization with cisplatin and thiotepa with oral thalidomide for primary liver cancer and liver metastases Journal of Clinical Oncology. 22: 4137-4137. DOI: 10.1200/Jco.2004.22.14_Suppl.4137 |
0.329 |
|
| 2003 |
Robles C, Furst AJ, Sriratana P, Lai S, Chua L, Donnelly E, Solomon J, Sundaram M, Feun L, Savaraj N. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer. Oncology Reports. 10: 885-9. PMID 12792740 DOI: 10.3892/Or.10.4.885 |
0.344 |
|
| 2003 |
Hu YP, Haq B, Carraway KL, Savaraj N, Lampidis TJ. Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Biochemical Pharmacology. 65: 1419-25. PMID 12732353 DOI: 10.1016/S0006-2952(03)00086-8 |
0.397 |
|
| 2003 |
Feun LG, O'Brien C, Molina E, Rodriguez M, Jeffers L, Schiff ER, Marini A, Savaraj N, Ardalan B. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial. Journal of Cancer Research and Clinical Oncology. 129: 17-20. PMID 12618896 DOI: 10.1007/S00432-002-0398-2 |
0.302 |
|
| 2003 |
He L, Chang HX, Chou TC, Savaraj N, Cheng CC. Design of antineoplastic agents based on the '2-phenylnaphthalene-type' structural pattern--synthesis and biological activity studies of 11H-indolo[3.2-c]quinoline derivatives. European Journal of Medicinal Chemistry. 38: 101-7. PMID 12593920 DOI: 10.1016/S0223-5234(02)01420-4 |
0.336 |
|
| 2003 |
Savaraj N, Wu C, Wangpaichitr M, Kuo MT, Lampidis T, Robles C, Furst AJ, Feun L. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. International Journal of Oncology. 23: 173-179. DOI: 10.3892/Ijo.23.1.173 |
0.374 |
|
| 2002 |
Liu H, Savaraj N, Priebe W, Lampidis TJ. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochemical Pharmacology. 64: 1745-51. PMID 12445863 DOI: 10.1016/S0006-2952(02)01456-9 |
0.336 |
|
| 2002 |
Feun LG, Savaraj N, Hurley J, Marini A. Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma. Cancer Investigation. 20: 357-61. PMID 12025231 DOI: 10.1081/Cnv-120001181 |
0.361 |
|
| 2001 |
Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry. 40: 5542-7. PMID 11331019 DOI: 10.1021/Bi002426W |
0.395 |
|
| 2001 |
Lin-Lee YC, Tatebe S, Savaraj N, Ishikawa T, Kuo MT. Differential sensitivities of the MRP gene family and γ-glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status Biochemical Pharmacology. 61: 555-563. PMID 11239498 DOI: 10.1016/S0006-2952(00)00592-X |
0.321 |
|
| 2000 |
Hu YP, Moraes CT, Savaraj N, Priebe W, Lampidis TJ. ρ0 Tumor cells: A model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs Biochemical Pharmacology. 60: 1897-1905. PMID 11108806 DOI: 10.1016/S0006-2952(00)00513-X |
0.379 |
|
| 2000 |
Zou J, Landy H, Feun L, Xu R, Lampidis T, Wu CJ, Furst AJ, Savaraj N. Correlation of a unique 220-kDa protein with vitamin D sensitivity in glioma cells. Biochemical Pharmacology. 60: 1361-5. PMID 11008130 DOI: 10.1016/S0006-2952(00)00438-X |
0.336 |
|
| 2000 |
Feun LG, Savaraj N, Hurley J, Marini A, Lai S. A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma. Cancer. 88: 584-588. PMID 10649251 DOI: 10.1002/(Sici)1097-0142(20000201)88:3<584::Aid-Cncr14>3.0.Co;2-# |
0.383 |
|
| 1999 |
Feun LG, Reddy KR, Scagnelli T, Yrizarry JM, Guerra JJ, Russell E, Schwartz M, Savaraj N, Livingstone AS, Levi JU, Jeffers LJ, Ardalan B, Schiff ER. A phase I study of chemoembolization with cisplatin, thiotepa, and lipiodol for primary and metastatic liver cancer. American Journal of Clinical Oncology. 22: 375-80. PMID 10440193 DOI: 10.1097/00000421-199908000-00010 |
0.345 |
|
| 1998 |
Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochemical and Biophysical Research Communications. 247: 859-63. PMID 9647783 DOI: 10.1006/Bbrc.1998.8887 |
0.328 |
|
| 1998 |
Kuo MT, Bao J, Furuichi M, Yamane Y, Gomi A, Savaraj N, Masuzawa T, Ishikawa T. Frequent coexpression of MRP/GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues. Biochemical Pharmacology. 55: 605-15. PMID 9515571 DOI: 10.1016/S0006-2952(97)00494-2 |
0.37 |
|
| 1997 |
Savaraj N, Wu CJ, Xu R, Lampidis T, Lai S, Donnelly E, Solomon J, Feun LG. Multidrug-resistant gene expression in small-cell lung cancer. American Journal of Clinical Oncology. 20: 398-403. PMID 9256898 DOI: 10.1097/00000421-199708000-00016 |
0.413 |
|
| 1997 |
Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L, Savaraj N, Tapiero H, Priebe W. Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry. 36: 2679-85. PMID 9054575 DOI: 10.1021/Bi9614489 |
0.315 |
|
| 1996 |
Feun LG, Savaraj N, Solomon J, Liebmann A, Hurley J. Phase II trial of mitoxantrone and cisplatin in advanced non-small-cell lung cancer. American Journal of Clinical Oncology. 19: 190-192. PMID 8610648 DOI: 10.1097/00000421-199604000-00021 |
0.387 |
|
| 1995 |
Feun LG, Robinson WA, Savaraj N, Gonzalez R, Liebmann A, Offenhauser K, Clendeninn NJ. Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma. American Journal of Clinical Oncology. 18: 488-490. PMID 8526190 DOI: 10.1097/00000421-199512000-00006 |
0.341 |
|
| 1995 |
Cassileth PA, Podack E, Sridhar K, Savaraj N, Hanlon J. Phase I Study of Transfected Cancer Cells Expressing the Interleukin-2 Gene Product in Limited Stage Small Cell Lung Cancer. University of Miami, Miami, Florida Human Gene Therapy. 6: 369-383. PMID 7779919 DOI: 10.1089/Hum.1995.6.3-369 |
0.331 |
|
| 1995 |
Feun LG, Savaraj N, Moffat FL, Robinson D, Liebmann A, Hurley J, Raub WA, Richman SP. Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. Melanoma Research. 5: 273-276. PMID 7496164 DOI: 10.1097/00008390-199508000-00011 |
0.357 |
|
| 1994 |
Cheng CC, Dong Q, Liu DF, Luo YL, Liu LF, Chen AY, Yu C, Savaraj N, Chou TC. Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives. Journal of Medicinal Chemistry. 36: 4108-12. PMID 8258835 DOI: 10.1021/Jm00077A016 |
0.347 |
|
| 1994 |
Feun LG, Savaraj N, Benedetto P, Waldman S, Collier M, Clendennin NJ. Oral piritrexim in advanced bladder cancer: an effective drug after progression on MVAC chemotherapy? American Journal of Clinical Oncology. 17: 448-51. PMID 8092120 DOI: 10.1097/00000421-199410000-00019 |
0.358 |
|
| 1994 |
Feun LG, Savaraj N, Hung S, Reddy R, Jeffers L, Benedetto P, Livingstone AS, Ardalan B, Levi JU, Parker T, Schiff ER. A Phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma American Journal of Clinical Oncology. 17: 393-395. PMID 8092109 DOI: 10.1097/00000421-199410000-00007 |
0.347 |
|
| 1994 |
Savaraj N, Lampidis TJ, Zhao JY, Wu CJ, Teeter LD, Kuo MT. Two multidrug-resistant Friend leukemic cell lines selected with different drugs exhibit overproduction of different P-glycoproteins. Cancer Investigation. 12: 138-44. PMID 7907527 DOI: 10.3109/07357909409024869 |
0.352 |
|
| 1994 |
Feun LG, Savaraj N, Landy HJ. Drug resistance in brain tumors Journal of Neuro-Oncology. 20: 165-176. PMID 7807193 DOI: 10.1007/Bf01052726 |
0.35 |
|
| 1993 |
Sridhar KS, Thurer RJ, Markoe AM, Chatoor HT, Fountzilas G, Raub WJ, Savaraj N, Beattie EJ. Multidisciplinary approach to the treatment of locally and regionally advanced non‐small cell lung cancer: University of Miami experience Seminars in Surgical Oncology. 9: 114-119. PMID 8387688 DOI: 10.1002/Ssu.2980090209 |
0.348 |
|
| 1993 |
Feun LG, Blyden G, Yrizarry J, Dorvil M, Waldman S, Benedetto P, Donnelly E, Curtas J, George M, Savaraj N. Clinical and pharmacological study of intrahepatic artery infusion of Thiotepa Cancer Biotherapy. 8: 43-48. PMID 7812348 DOI: 10.1089/Cbr.1993.8.43 |
0.34 |
|
| 1993 |
Savaraj N, Feun LG, Blyden G, Yrizarry JM, Hsiang JTG, Curtas J, Waldman S, Post JD, Benedetto P, Landy H, Guerra JJ. A pilot clinical and pharmacological study of intra-arterial infusion of Thiotepa Cancer Biotherapy. 8: 37-42. PMID 7812347 DOI: 10.1089/Cbr.1993.8.37 |
0.334 |
|
| 1992 |
Ardalan B, Stridhar K, Reddy R, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Livingstone A. Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. International Journal of Radiation Oncology Biology Physics. 22: 511-514. PMID 1735689 DOI: 10.1016/0360-3016(92)90864-E |
0.321 |
|
| 1992 |
Sridhar KS, Hussein AM, Benedetto P, Ardalan B, Savaraj N, Richman SP. Phase II trial of 4′-O-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma Cancer. 70: 1591-1597. PMID 1516010 DOI: 10.1002/1097-0142(19920915)70:6<1591::Aid-Cncr2820700624>3.0.Co;2-6 |
0.363 |
|
| 1992 |
Moore MLG, Savaraj N, Feun LG, Donnelly E. Successful therapy of peritoneal mesothelioma with intraperitoneal chemotherapy alone: A case report American Journal of Clinical Oncology: Cancer Clinical Trials. 15: 528-530. PMID 1449118 DOI: 10.1097/00000421-199212000-00013 |
0.345 |
|
| 1991 |
Feun LG, Savaraj N, Landy H, Levin H, Lampidis T. Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors. Journal of Neuro-Oncology. 9: 159-63. PMID 2175770 DOI: 10.1007/Bf02427837 |
0.391 |
|
| 1991 |
Feun LG, Gonzalez R, Savaraj N, Hanlon J, Collier M, Robinson WA, Clendeninn NJ. Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 9: 464-7. PMID 1999717 DOI: 10.1200/Jco.1991.9.3.464 |
0.338 |
|
| 1991 |
Feun LG, Savaraj N, Benedetto P, Hanlon J, Sridhar KS, Collier M, Richman S, Liao SH, Clendeninn NJ. Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies. Journal of the National Cancer Institute. 83: 51-5. PMID 1984518 DOI: 10.1093/Jnci/83.1.51 |
0.313 |
|
| 1991 |
Ardalan B, Sridhar KS, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Fodor M, Livingstone A. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Cancer. 68: 1242-1246. PMID 1873776 DOI: 10.1002/1097-0142(19910915)68:6<1242::Aid-Cncr2820680610>3.0.Co;2-5 |
0.35 |
|
| 1991 |
Sridhar KS, Hussein AM, Benedetto P, Waldman SM, Feun LG, Savaraj N, Richman SP, Ardalan B, Desai P. Phase II trial of mitoxantrone in head and neck carcinoma American Journal of Clinical Oncology: Cancer Clinical Trials. 14: 298-304. PMID 1650529 DOI: 10.1097/00000421-199108000-00005 |
0.346 |
|
| 1990 |
Lampidis TJ, Castello C, del Giglio A, Pressman BC, Viallet P, Trevorrow KW, Valet GK, Tapiero H, Savaraj N. Relevance of the chemical charge of rhodamine dyes to multiple drug resistance. Biochemical Pharmacology. 38: 4267-71. PMID 2597199 DOI: 10.1016/0006-2952(89)90525-X |
0.328 |
|
| 1990 |
Feun LG, Maor M, Stewart DJ, Leavens ME, Savaraj N, Bodey GP. Pilot study of PCNU and cranial radiation therapy in the treatment of patients with malignant gliomas. Oncology. 47: 389-92. PMID 2170890 DOI: 10.1159/000226854 |
0.31 |
|
| 1990 |
Feun LG, Lee YY, Plager C, Papadopoulos N, Savaraj N, Charnsangavej C, Benjamin RS, Wallace S. Intracarotid cisplatin-based chemotherapy in patients with malignant melanoma and central nervous system (CNS) metastases American Journal of Clinical Oncology: Cancer Clinical Trials. 13: 448-451. PMID 1699402 DOI: 10.1097/00000421-199010000-00017 |
0.344 |
|
| 1989 |
Hussein AM, Savaraj N, Feun LG, Ganjei P, Donnelly E. Carcinomatous meningitis from transitional cell carcinoma of the bladder: case report. Journal of Neuro-Oncology. 7: 255-260. PMID 2795119 DOI: 10.1007/Bf00172919 |
0.362 |
|
| 1988 |
Feun LG, Savaraj N, Legha SS, Silva EG, Benjamin RS, Burgess MA. Chemotherapy for metastatic Merkel cell carcinoma: Review of the M.D. Anderson Hospital's experience Cancer. 62: 683-685. PMID 3293760 DOI: 10.1002/1097-0142(19880815)62:4<683::Aid-Cncr2820620406>3.0.Co;2-J |
0.396 |
|
| 1988 |
Chong CDK, Logothetis CJ, Savaraj N, Fritsche HA, Gietner AM, Samuels ML. The Correlation of Vinblastine Pharmacokinetics to Toxicity in Testicular Cancer Patients The Journal of Clinical Pharmacology. 28: 714-718. PMID 3216038 DOI: 10.1002/J.1552-4604.1988.Tb03205.X |
0.306 |
|
| 1987 |
Feun LG, Lee YY, Yung WKA, Savaraj N, Wallace S. Intracarotid VP-16 in malignant brain tumors. Journal of Neuro-Oncology. 4: 397-401. PMID 3572470 DOI: 10.1007/Bf00195611 |
0.325 |
|
| 1987 |
Vogel CL, Gorowski E, Davila E, Eisenberger M, Kosinski J, Agarwal RP, Savaraj N. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. Investigational New Drugs. 5: 187-198. PMID 3115912 DOI: 10.1007/Bf00203545 |
0.335 |
|
| 1986 |
Feun LG, Lee YY, Yung WK, Charnsangavej C, Savaraj N, Tang RA, Wallace S. Phase II trial of intracarotid BCNU and cisplatin in primary malignant brain tumors. Cancer Drug Delivery. 3: 147-56. PMID 3708537 DOI: 10.1089/Cdd.1986.3.147 |
0.389 |
|
| 1986 |
Pasterz R, Savaraj N, Burgess M. Prognostic factors in metastatic carcinoma of unknown primary Journal of Clinical Oncology. 4: 1652-1657. PMID 3095502 DOI: 10.1200/Jco.1986.4.11.1652 |
0.346 |
|
| 1985 |
Feldman LD, Feun LG, Benjamin RS, Yap BS, Plager C, Papadopoulos N, Savaraj N, Burgess MA, Bodey GP. A phase II trial of PCNU in patients with malignant melanoma and central nervous system metastases American Journal of Clinical Oncology: Cancer Clinical Trials. 8: 215-217. PMID 4050740 DOI: 10.1097/00000421-198506000-00004 |
0.37 |
|
| 1985 |
Obbens EA, Feun LG, Leavens ME, Savaraj N, Stewart DJ, Gutterman JU. Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies. Journal of Neuro-Oncology. 3: 61-67. PMID 2987429 DOI: 10.1007/Bf00165173 |
0.358 |
|
| 1984 |
Feun LG, Wallace S, Yung WKA, Lee YY, Leavens ME, Moser R, Savaraj N, Burgess MA, Plager C, Benjamin RS. Phase-I trial of intracarotid BCNU and cisplatin in patients with malignant intracerebral tumors Cancer Drug Delivery. 1: 239-245. PMID 6544123 DOI: 10.1089/Cdd.1984.1.239 |
0.33 |
|
| 1984 |
Feun LG, Wallace S, Stewart DJ, Chuang VP, Yung WK, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Young SE. Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors Cancer. 54: 794-799. PMID 6331626 DOI: 10.1002/1097-0142(19840901)54:5<794::Aid-Cncr2820540503>3.0.Co;2-F |
0.361 |
|
| 1984 |
Feun LG, Yung WKA, Leavens ME, Burgess MA, Obbens EA, Bedikian AY, Savaraj N, Stewart DJ, Benjamin RS, Fields WS, Bodey GP. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors Journal of Neuro-Oncology. 2: 13-17. PMID 6088722 DOI: 10.1007/Bf00165153 |
0.372 |
|
| 1983 |
Guo ZG, Savaraj N, Feun LG, Lu K, Stewart DJ, Luna M, Benjamin RS, Loo TL. Tumor penetration of AMSA in man. Cancer Investigation. 1: 475-8. PMID 6689404 DOI: 10.3109/07357908309020272 |
0.347 |
|
| 1983 |
Feun LG, Stewart DJ, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Bodey GP. A phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in recurrent malignant brain tumors Journal of Neuro-Oncology. 1: 45-48. PMID 6678305 DOI: 10.1007/Bf00153640 |
0.368 |
|
| 1982 |
Savaraj N, Lu K, Valdivieso M, Burgess M, Umsawasdi T, Benjamin RS, Loo TL. Clinical kinetics of 1, 4-dihydroxy-5,8-bis [(2-[(2-hydroxyethyl) amino] ethyl] amino ]-9, 10-anthracenedione. Clinical Pharmacology & Therapeutics. 31: 312-316. PMID 7060314 DOI: 10.1038/Clpt.1982.39 |
0.303 |
|
| 1980 |
Savaraj N, Troner MB. Aminoglutethimide in the management of metastatic breast cancer Medical and Pediatric Oncology. 8: 251-263. PMID 7464686 DOI: 10.1002/Mpo.2950080307 |
0.316 |
|
| Show low-probability matches. |